Piramal Pharma Solutions Expands US Injectables Facility with $80 Million Investment
Piramal Pharma Solutions' Expansion Plan
Piramal Pharma Solutions (PPS), a leading Contract Development and Manufacturing Organization (CDMO), is embarking on an ambitious expansion of its sterile injectables facility located in Lexington, Kentucky. This significant investment of $80 million aims to bolster the site’s production capabilities, set to more than double by the first quarter of 2027.
Investment and Capacity Growth
Currently capable of producing 104 product batches per year, the Lexington site will enhance its output to over 240 annual batches upon completion of the expansion. This increase will cater to the rising global {injectables) market, predicted to surpass $20 billion by 2028.
Strategic Importance of the Facility
- 24,000 square feet of additional manufacturing space will be added.
- New laboratory facilities and advanced machinery are planned for installation.
- The site is integral to Piramal’s antibody-drug conjugate program, known as ADCelerate.
Market Trends and Future Outlook
According to Nandini Piramal, chairperson of Piramal Pharma, filling the commercial manufacturing gap positions the Lexington site effectively within the rapidly expanding injectables market. The ongoing evolution in client demand has resulted in an uptick in Requests for Proposal (RFPs) since March 2024, reflecting a positive trend for the CDMO.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.